Abstract-Congestive heart failure is characterized by a sympathetic activation that is coupled with a baroreflex impairment. Whether these alterations are affected by clonidine is unknown. In 26 normotensive patients age 58.0Ϯ1.1 years (meanϮSEM) affected by congestive heart failure (New York Heart Association functional class II or III) and treated with furosemide and enalapril, we measured mean arterial pressure, heart rate, venous plasma norepinephrine, and muscle sympathetic nerve traffic (microneurography) at rest and during baroreceptor stimulation and deactivation caused by stepwise intravenous infusions of phenylephrine and nitroprusside, respectively. Measurements were repeated after a 2-month administration of transdermal clonidine patch (14 patients) or placebo (12 patients) according to a double-blind, randomized sequence. Clonidine caused a slight, nonsignificant reduction in mean arterial pressure and heart rate without affecting exercise capacity and echocardiographically determined left ventricular ejection fraction. In contrast, both plasma norepinephrine and sympathetic nerve traffic were significantly reduced (Ϫ46.8% and Ϫ26.7%, respectively; PϽ0.01 for both). This reduction was coupled with no change in cardiac and sympathetic baroreflex responses. Transdermal placebo administration for a 2-month period did not affect any of the above-mentioned variables. Thus, in congestive heart failure patients who are undergoing conventional drug treatment, chronic clonidine administration exerts marked sympathoinhibitory effects without adversely affecting cardiac functions and clinical state.
S
everal studies have shown that in congestive heart failure (CHF), survival is inversely related to the degree of sympathetic activation that characterizes this clinical condition. [1] [2] [3] [4] They have also shown that the reduction in mortality observed with the administration of a number of drugs may be related to sympathetic deactivation, which is thus regarded as a desirable therapeutic goal in all patients in whom cardiac function is impaired. 5, 6 Sympathetic deactivation in CHF has been documented for ACE inhibitors, digitalis, and ␤-blockers. 3, [7] [8] [9] [10] [11] Recent observations have shown that in CHF patients, acute administration of clonidine is accompanied by a reduction in norepinephrine (NE) spillover from sympathetic nerve terminals, 12 and plasma NE is markedly reduced after repeated intravenous doses of the drug over a 1-week period. 13 The aim of the present study has been to determine the sympathoinhibitory effects of clonidine in CHF under chronic therapeutic conditions and in the context of a controlled experimental design. Sympathetic activity was assessed not only by plasma NE but also by microneurography from a peroneal nerve, which allows direct quantification of sympathetic nerve traffic to the skeletal muscle districts (MSNA). 8, 9 Baroreflex modulation of MSNA was also studied before and after chronic administration of the drug to investigate whether any drug-induced sympathoinhibition might depend on an enhancement of the reflex inhibitory control, as has been reported for the sympathoinhibition induced by several drugs in CHF 8, 9, 14 and by clonidine in hypertension. 15 
Methods

Study Population
Our study was performed in 30 patients (22 (2) no clinical or laboratory evidence of valvular heart disease, renal insufficiency, diabetes mellitus, or other conditions known to impair autonomic function; (3) no history or objective evidence of hypertension; (4) body mass index Ͻ27 kg/m 2 ; (5) presence of sinus rhythm; (6) no myocardial infarction or stroke in the preceding 6 months; and (7) no history of excessive alcohol consumption. The CHF condition was ascribed to ischemic heart disease in 21 patients and to nonischemic heart disease in 9 patients.
Measurements
Blood pressure (BP) was measured by (1) a mercury sphygmomanometer, with the first and fifth Korotkoff sounds being taken as markers of systolic and diastolic values, respectively, and (2) a finger photoplethysmographic device (Finapres 2300, Ohmeda) capable of providing accurate and reproducible beat-to-beat systolic and diastolic values. 8 Heart rate (HR) was continuously monitored by a cardiotachometer triggered by the R wave of an ECG lead. Respiration rate was monitored by a strain-gauge pneumograph positioned at the midchest level. Measurements included an echocardiogram performed in M-mode and in B-mode. This allowed us to assess left ventricular end-diastolic and end-systolic diameters and volumes and to calculate left ventricular ejection fraction (LVEF) and fractional shortening. 16 Echocardiographic data were collected by a single operator unaware of the experimental design. The within-operator coefficients of variation of left ventricular diameters and volume measurements (ie, within-operator reproducibility) were 5.9% and 5.4%, respectively.
Multiunit recording of efferent postganglionic MSNA was obtained through a tungsten microelectrode inserted into the right or left peroneal nerve, as previously described, 8, 9 and displayed with BP, HR, and respiratory movements on thermal paper by an ink polygraph (Gould 3800). The muscle nature of MSNA was assessed according to criteria outlined in previous studies, 8, 9 and the recording was accepted only if the signal-to-noise ratio was Ͼ3. Under baseline resting conditions, MSNA was quantified as bursts per minute and bursts per 100 heartbeats. This quantification was shown to be highly reproducible, ie, to differ by only 4.3% when assessed on 2 separate occasions by a single investigator. 17 Plasma NE and plasma renin activity were assayed by high-performance liquid chromatography 18 and radioimmunoassay, 19 respectively, from a blood sample drawn from a cannula placed in an antecubital vein.
Baroreceptor modulation of MSNA and HR was assessed by intravenous infusion of vasoactive drugs. 20 Briefly, phenylephrine (PHE) was incrementally infused through the cannula that was placed in the antecubital vein at a dose of 0.3, 0.6, and 0.9 g · kg Ϫ1 · min
Ϫ1
. Nitroprusside (NTP) was also infused incrementally in an antecubital vein at a dose of 0.4, 0.8, and 1.2 g · kg Ϫ1 · min Ϫ1 . Each infusion was maintained for 5 minutes, and the drug initially infused was selected randomly. The end of the first infusion was spaced from the beginning of the second one by a recovery time of 45 minutes. Mean BP (diastolic BP plus one third of pulse pressure), MSNA, and HR were averaged for 5 minutes before infusion and for 5 minutes of each step infusion. We estimated baroreceptor modulation of MSNA and HR by calculating (1) the change in the number of bursts per minute; (2) the percent change in total integrated activity, ie, mean burst amplitude times number of bursts over time; and (3) the absolute change in HR in relation to the change in mean BP induced by each dose of PHE and NTP.
Protocol and Data Analysis
All patients were followed up on an outpatient basis. After a screening visit, they were asked to maintain their diuretic regimen and to standardize their ACE inhibitor treatment by taking enalapril at a morning oral dose of 10 mg for 2 weeks. They were then asked to come to the outpatient clinic in the morning, after a 48-hour abstinence from smoking (in the 7 smokers) and alcohol consumption. After assumption of the supine position, patients were fitted with intravenous cannulas, the ECG lead, the finger BP recording device, and microelectrodes for MSNA recording. After a 30-minute interval, a blood sample was drawn, and BP was then measured 3 times with a mercury sphygmomanometer, the 3 values being averaged. BP, HR, MSNA, and respiration rate were measured continuously during an initial 10-minute baseline condition, the stepwise infusion of one vasoactive drug, a second 10-minute baseline condition, and the stepwise infusion of the second vasoactive drug. In half of the patients, PHE was infused first, whereas NTP was infused first in the remaining half. Echocardiography and the exercise tolerance test (cycloergometer) were performed in the afternoon. The exercise tolerance test began after a 5-minute rest in the sitting position and with an initial workload of 25 W and a subsequent workload increase of 25 W every 3 minutes until exercise-limiting symptoms, ECG abnormalities, or abnormalities of BP values (taken every minute during each step) appeared. Subjects were then randomized in a double-blind fashion to add to existing treatment either a transdermal clonidine patch, which released 0.1 mg of the drug daily, or placebo. In both instances, no dietary or lifestyle changes were advised. Subjects were asked to replace the patch every 7 days, to undergo a clinical visit after 4 weeks, and then to double the patch size to provide a release of clonidine of 0.2 mg daily for 4 additional weeks. Adherence to treatment was verified by counting the number of patches used. The 2-month treatment period ended with a clinical visit, a second experimental session, an echocardiographic examination, and an exercise test as done for the first study. The study protocol was approved by the Ethics Committee of our institution. All patients gave written consent to the study after being informed of its nature and purpose.
Data were analyzed by a single investigator unaware of the patients' status in the active treatment or placebo group. Values from individual subjects were averaged for the 2 groups and expressed as meanϮSEM. Statistical significance of the difference in mean values was assessed by 2-way ANOVA. The 2-tailed t test for unpaired observations was used to identify the difference between groups. The 2-tailed t test for paired observations was used to identify the difference between resting conditions and baroreceptor stimulation and deactivation and the difference between baseline and treatment values in either group. The Bonferroni correction for multiple comparisons was used. A value of PϽ0.05 was taken as statistically significant.
Results
In 4 patients (3 with CHF caused by ischemic heart disease and 1 with CHF caused by nonischemic heart disease), microneurography failed to obtain an initial MSNA recording of acceptable quality. The data were thus derived from a total of 26 patients, 14 of whom were randomized to clonidine and 12 to placebo. As shown in the Table, the 2 groups had a similar age and gender distribution. At baseline, the 2 groups showed a similar body mass index, BP, LVEF, left ventricular end-diastolic diameter, left ventricular fractional shortening, respiratory rate, and exercise tolerance time with virtually superimposable values for plasma NE, plasma renin activity, and MSNA. In both the clonidine and placebo groups, LVEF and exercise tolerance time were not altered after 2 months. This was also the case for HR, sphygmomanometric BP, and plasma renin activity, although in the clonidine group, these variables showed a slight, nonsignificant decrease. The number of sympathetic bursts per minute, number of bursts corrected for HR, and plasma NE were not modified by placebo, but they were all consistently reduced by clonidine, the reduction amounting on average to Ϫ25.7%, Ϫ26.7%, and Ϫ46.8%, respectively (Figure 1) . Figure 2 shows the results obtained during baroreceptor stimulation and deactivation by infusion of vasoactive drugs. HR and MSNA (expressed both as bursts/min and as percent total integrated activity) were progressively reduced by progressively increasing mean BP via PHE and were progressively increased by progressively reducing mean BP via NTP. All responses were superimposable before and after clonidine administration. Baroreflex responses to vasoactive drug infusions also were superimposable between the first and second studies in the placebo group.
There was no change in NYHA class over the 2 months of clonidine or placebo administration. In the clonidine-treated group, the only side effect was xerostomia, which was reported by 6 patients.
Discussion
Our study provides the first report on the effects of prolonged clonidine administration on sympathetic nerve traffic and baroreceptor cardiovascular control in CHF. The main finding is represented by the evidence that in CHF patients undergoing treatment with furosemide and enalapril, the administration of transdermal clonidine for 2 months was accompanied not only by a consistent and marked decrease in plasma NE but also by a clear-cut and pronounced reduction in MSNA values, which were unaltered in the group that was given placebo. This confirms previous findings that clonidine reduces the elevated plasma NE values that characterize CHF. 12, 13 It adds 3 new pieces of evidence to the previous findings, however. First, the reduction in plasma NE is not due to an increased tissue clearance of this substance secondary to an increased blood flow but rather to a true reduction in central sympathetic drive. Second, the sympathoinhibition caused by clonidine in CHF also occurs to a major degree when the drug is given on a chronic basis. Finally, this inhibition also takes place to a major degree in patients who are already undergoing treatment with an ACE inhibitor, ie, a drug that exerts clear sympathoinhibitory effects in CHF. 
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Previous studies in hypertensive animals and humans have shown that the sympathoinhibitory effects of clonidine may be exerted either through a central mechanism (stimulation of both ␣ 2 -adrenergic receptors and imidazoline-1 receptors 21 ) or through the arterial baroreflex, 22 ie, through an enhancement of the sympathetic restraint exerted by this reflex. In our CHF patients, however, sudden and short-lasting BP changes induced by vasoactive drugs caused reflex changes in HR and in MSNA that were superimposable before and after chronic administration of clonidine. This allows us to conclude that, at variance from what has been documented for other drugs, 8, 14 clonidine does not potentiate the baroreflex in CHF. It also allows us to speculate that in this condition, the sympathoinhibitory influence of this drug is accounted for mainly by its central effects.
In our CHF patients, the reduction in plasma NE induced by chronic clonidine administration was substantially greater than the reduction in MSNA (Ϫ46.8% versus Ϫ26.7%). This is unlikely to be explained by an increase in tissue clearance of the adrenergic neurotransmitter, because previous studies have shown systemic clearance of NE to be unaffected by acute administration of clonidine in CHF patients, 12, 23 and because in our patients, administration of clonidine did not lead to an increase in LVEF, and therefore presumably to an increase in tissue blood flow that could have favored disposal of NE secreted from sympathetic nerve terminals. 24 It is more likely to be explained by an additional sympathoinhibitory influence exerted by the drug at the peripheral level, because ␣ 2 -adrenergic stimulation inhibits NE release from sympathetic nerve terminals, 25 thus favoring a reduction in plasma NE. A third explanation should be also considered, namely, that the greater reduction in plasma NE compared with MSNA observed during treatment with clonidine might reflect a greater effect of clonidine on sympathetic activity in districts other than that explored in the present study. Because skin sympathetic nerve traffic is not increased in CHF, 26 the most likely candidates are the splanchnic circulation, the kidney, and the heart. A greater sympathoinhibitory effect of clonidine on the heart is not in line with the observation that in our patients, the drug had only a modest bradycardic effect. However, HR is an inaccurate marker of cardiac and overall adrenergic drive. 27 Furthermore, recent observations indicate that in CHF, intravenous clonidine reduces cardiac NE spillover to a greater extent than systemic NE spillover. 12 Thus, the above possibility remains valid.
Our study has a potential limitation and clinical implications. The limitation is that because the patients we examined suffered from mildly symptomatic CHF with a modest impairment in left ventricular function, our conclusions cannot be safely extrapolated to more severe CHF conditions. The clinical implications are that, confirming previous findings obtained in an acute clinical setting, 28 the sympathoinhibitory effects of chronic administration of this drug can be exerted in addition to that exerted by ACE inhibitor treatment, thereby leading to MSNA and plasma NE values virtually indistinguishable from those of healthy age-matched controls. 17 Thus, the addition of clonidine to current treatment of heart failure may more effectively remove a phenomenon that has been shown to have adverse prognostic implications. [1] [2] [3] [4] This may also be obtained by administration of a ␤-blocker, which has been shown to favorably affect CHF prognosis. 29 -31 Clonidine, however, by inhibiting central sympathetic outflow, may counteract the adverse effects on both the heart and the peripheral circulation induced by the generalized sympathetic activation typical of CHF and may represent an alternative to ␤-blockers, particularly when these drugs are contraindicated or not tolerated. It should be emphasized, however, that use of this drug in CHF will have to be further tested in clinical studies, because although clonidine did not cause any deterioration in cardiac function and exercise capacity in the present study, inhibition of sympathetic activity by another drug that also exerts central sympathoinhibitory effects, such as moxonidine, 32 has not been shown to provide beneficial effects on clinical outcome (Jay Cohn, MD, unpublished data, 1999). The reasons for this negative result remain to be clarified, although the possibility exists that the dose of the drug used was too high.
